|
|
(29 intermediate revisions not shown.) |
Line 1: |
Line 1: |
- | {{STRUCTURE_1c5w| PDB=1c5w | SIZE=400| SCENE= |right|CAPTION=Human urokinase short chain (grey) and catalytic domain (green) complex with iodobenzine inhibitor and citrate, [[1c5w]] }}
| + | <StructureSection load='3ig6' size='350' side='right' caption='Human urokinase light chain fragment (pink) and catalytic domain (yellow) complex with inhibitor and phosphate, [[3ig6]]' scene='' > |
| + | == Function == |
| + | '''Urokinase''' (UK) or '''urokinase plasminogen activator''' or '''urokinase-type plasminogen activator''' is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin<ref>PMID:21711235</ref>. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage into catalytic domain (residues 179-431) and short chain (residues 156-178). |
| | | |
- | '''Urokinase''' (UK) is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage into catalytic domain (residues 179-431) and short chain (residues 156-178).
| + | == Relevance == |
| + | Increased levels of UK are associated with poor prognosis in patients with breast cancer and thus is used as prognostic markers for the disease<ref>PMID:15944776</ref>. |
| | | |
| + | == Structural highlights == |
| + | The <scene name='46/465442/Cv/10'>inhibitor of UK binds in the active site of UK</scene> and interacts with the active Ser of the catalytic triad<ref>PMID:19703768</ref>. Water molecules are shown as red spheres. |
| == 3D Structures of urokinase == | | == 3D Structures of urokinase == |
| + | [[Urokinase 3D Structures]] |
| + | </StructureSection> |
| | | |
- | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
| + | ==References== |
- | {{#tree:id=OrganizedByTopic|openlevels=0|
| + | <references /> |
- | | + | |
- | *Urokinase
| + | |
- | | + | |
- | **[[2i9a]] - hUK Hc N terminal (residues 21-163) - human<br />
| + | |
- | **[[1kdu]] – hUK kringle domain (residues 69-153) - NMR<br />
| + | |
- | **[[4dva]] – hUK catalytic domain (residues 179-431) <br />
| + | |
- | | + | |
- | *Urokinase catalytic domain complex with inhibitors
| + | |
- | | + | |
- | **[[4fu7]], [[4fu8]], [[4fu9]], [[4fub]] - hUK + inhibitor<br />
| + | |
- | **[[1fv9]] – hUK (mutant) + benzimidazole derivative – human<br />
| + | |
- | **[[1f5k]] - hUK (mutant) + benzamidine derivative<br />
| + | |
- | **[[1f5l]] - hUK (mutant) + amiloride derivative<br />
| + | |
- | **[[1f92]], [[1sc8]], [[1vj9]], [[1vja]], [[2o8t]], [[2o8u]], [[2o8w]], [[4h42]] - hUK (mutant) + inhibitor<br />
| + | |
- | **[[1owd]], [[1owe]], [[1owh]], [[1owi]], [[1owj]], [[1owk]], [[1sqa]], [[1sqo]], [[1u6q]], [[1sqt]], [[4fuc]], [[4fud]], [[4fue]], [[4fuf]], [[4fug]], [[4fuh]], [[4fui]], [[4fuj]]- hUK + naphthamidine inhibitor<br />
| + | |
- | **[[1ejn]] - hUK (mutant) + urea derivative inhibitor<br />
| + | |
- | **[[2vin]], [[2vio]], [[2vip]], [[2viq]], [[2viv]], [[2viw]] - hUK (mutant) + mexiletine derivative<br />
| + | |
- | **[[3qn7]], [[4jk5]], [[4jk6]] - hUK (mutant) + peptide inhibitor<br />
| + | |
- | **[[2vnt]], [[2r2w]] - hUK + guanidine derivative<br />
| + | |
- | **[[1w0z]], [[1w10]], [[1w11]], [[1w12]], [[1w13]], [[1w14]] - hUK + alanineamide derivative<br />
| + | |
- | | + | |
- | *Urokinase C terminal complex with inhibitors
| + | |
- | | + | |
- | **[[3kgp]] – hUK Hc C terminal (mutant) + benzoic acid derivative<br />
| + | |
- | **[[3khv]] - hUK Hc C terminal (mutant) + methanol derivative<br />
| + | |
- | **[[3mwi]] - hUK Hc C terminal (mutant) + amidine derivative<br />
| + | |
- | **[[3ox7]], [[3oy5]], [[3oy6]] - hUK Hc C terminal (mutant) + peptide inhibitor<br />
| + | |
- | **[[3kid]], [[3mhw]] - hUK Hc C terminal (mutant) + aminobenzothiazole derivative<br />
| + | |
- | **[[2nwn]], [[4gly]] - hUK Hc C terminal + cyclic peptide<br />
| + | |
- | **[[3m61]] - hUK Hc C terminal (mutant) + cyclic peptide
| + | |
- | | + | |
- | *Urokinase short chain + catalytic domain complex with inhibitors
| + | |
- | | + | |
- | **[[1lmw]] – hUK A+B catalytic domain + EGRCMK<br />
| + | |
- | **[[1c5w]], [[1c5x]], [[1c5y]], [[1c5z]] - hUK A+B chain catalytic domain + carboxamidine derivative<br />
| + | |
- | **[[1gi7]], [[1gi8]], [[1gi9]], [[1gj7]], [[1gj8]], [[1gj9]], [[1gja]], [[1gjb]], [[1gjc]], [[1gjd]] - hUK A+B chain catalytic domain (mutant) + carboxamidine derivative<br />
| + | |
- | **[[1o3p]], [[1o5a]], [[1o5b]], [[1o5c]] - hUK A+B chain catalytic domain (mutant) + benzenolate derivative<br />
| + | |
- | **[[3ig6]] – hUK A+B chain catalytic domain + inhibitor<br />
| + | |
- | | + | |
- | *Urokinase complex with protein
| + | |
- | | + | |
- | **[[2fd6]] – hUK Hc N terminal + antibody + UK receptor<br />
| + | |
- | **[[3bt1]], [[3bt2]] - hUK Hc N terminal + vitronectin + UK receptor<br />
| + | |
- | **[[3laq]], [[3u73]] - hUK Hc N terminal + UK receptor<br />
| + | |
- | **[[3pb1]] - hUK Hc C terminal (mutant) + UK inhibitor<br />
| + | |
- | **[[2i9b]] - hUK Hc N terminal + UK receptor (mutant)<br />
| + | |
- | **[[4dw2]] - hUK B chain catalytic domain + antibody<br />
| + | |
- | }}
| + | |
- | | + | |
| | | |
| [[Category:Topic Page]] | | [[Category:Topic Page]] |